Janus Henderson Group PLC Raises Stock Holdings in Roivant Sciences Ltd. $ROIV

Janus Henderson Group PLC boosted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 6.1% during the first quarter, Holdings Channel.com reports. The firm owned 3,095,448 shares of the company’s stock after purchasing an additional 177,339 shares during the quarter. Janus Henderson Group PLC’s holdings in Roivant Sciences were worth $85,790,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. UBS Group AG lifted its position in shares of Roivant Sciences by 570.0% during the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares during the last quarter. Morgan Stanley grew its position in shares of Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after buying an additional 14,036,696 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Roivant Sciences by 365.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after buying an additional 8,621,567 shares during the last quarter. Norges Bank bought a new position in shares of Roivant Sciences during the 4th quarter worth approximately $112,750,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of Roivant Sciences during the 4th quarter worth approximately $76,272,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Activity

In related news, Director Daniel Allen Gold sold 12,380 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total value of $436,766.40. Following the transaction, the director directly owned 13,689,166 shares of the company’s stock, valued at $482,953,776.48. This represents a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $34.95, for a total value of $6,990,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,613,063 shares in the company, valued at approximately $56,376,551.85. The trade was a 11.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 2,055,913 shares of company stock valued at $69,639,633 over the last ninety days. 10.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ROIV shares. HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Roivant Sciences in a research note on Thursday, May 21st. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Guggenheim raised their price objective on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Citigroup boosted their target price on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Finally, TD Cowen upped their target price on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.59.

Roivant Sciences Trading Down 1.8%

Shares of Roivant Sciences stock opened at $33.91 on Friday. The firm’s 50 day simple moving average is $32.63 and its two-hundred day simple moving average is $29.05. The firm has a market capitalization of $24.39 billion, a price-to-earnings ratio of -56.52 and a beta of 1.11. Roivant Sciences Ltd. has a 12-month low of $10.90 and a 12-month high of $37.00.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.